- Fellowship - Parkland Health & Hospital System (1979-1981), Hematology Oncology
- Residency - Parkland Health & Hospital System (1977-1979), Internal Medicine
- Internship - Parkland Health & Hospital System (1976-1977), Internal Medicine
- Medical School - UT Southwestern Medical Center
Barbara Haley, M.D.
- Charles Cameron Sprague, M.D., Chair in Clinical Oncology
- Internal Medicine - Hematology/Oncology
- Breast Cancers
- Medical Treatment of Breast Cancer
During her career, Barbara Haley, M.D., has dedicated herself to treating breast cancer patients, understanding more about the disease, and advancing treatment options. She has been involved with remarkable transformations to treat breast cancer more effectively, while minimizing side effects for patients.
Dr. Haley’s expertise as a medical oncologist is applying and advancing therapeutic agents to treat breast cancer, including chemotherapy, hormonal therapy, and biologic agents. She is committed to understanding the entirety of a patient’s needs and delivering customized, comprehensive treatment plans.
Dr. Haley leads multiple clinical trials at UT Southwestern related to therapeutic treatments of breast cancer. She is a member of UT Southwestern’s Center for Breast Care’s Executive Committee. As part of this team, she spearheaded the Center’s comprehensive approach to screening, staging, and treating breast cancer. The result is a multidisciplinary approach to care that supports the patient by utilizing case conferences among team members, coordinated planning, screening for genetic mutations, an array of support services, and access to electronic medical records.
Dr. Haley has participated in groundbreaking national and international clinical trials, such as those involving HER-2, nonadjuvant therapies, genetic influences on lymphedema and potential evacuation, and the impact of breast cancer treatments on postmenopausal women. Her work with nanoparticles is supporting the development of new delivery systems for drugs that will be more effective in targeting breast cancer cells.
She has published numerous scientific articles on breast cancer. This includes the assessment of HER-2 in breast cancer treatment, and how zoledronic acid can affect bone loss in postmenopausal women receiving adjuvant therapy for breast cancer.
Dr. Haley is a Fellow of the American College of Physicians. She is a member of the American Society of Clinical Oncology and the American Society of Hematology, as well as the Texas Medical Association and Dallas County Medical Society.
After graduating from UT Southwestern Medical Center, Dr. Haley completed her internship, residency, and fellowship at Parkland Health & Hospital System. She was named the Charles Cameron Sprague, M.D., Chair in Clinical Oncology in 2006.
Dr. Haley has received local and national recognition, including Best Doctors in America by U.S. News & World Report, Best Doctors in Dallas by D Magazine, and a Super Doctor by Texas Monthly.
Meet Dr. Haley
Breast Cancer Specialist
Barbara Haley, M.D., specializes in medical oncology, with a total focus on breast cancer and emerging alternatives to treat the disease. Her commitment to patients: go above and beyond standard care.
As a lead investigator for breast cancer therapeutic treatments at UT Southwestern Medical Center, Dr. Haley’s work involves studies that have led to significant advancements in chemotherapy, hormonal therapy, and biologic therapy. This includes new alternatives and improving the effectiveness of conventional therapies.
"Patients do not have to fly to Houston for access to the newest breast cancer treatments. Our team at UT Southwestern offers them comprehensive care and services that take into consideration the total needs of a breast cancer patient.”
For example, she participated in a national study on new mTOR inhibitors, a kinase that affects the growth of cancer cells. This anticancer agent provides an option to delay chemotherapy for patients with estrogen-reception (ER) and metastatic breast cancer. These findings led to a new drug approved by the FDA in July 2012.
Dr. Haley has gained national recognition for work related to asses HER-2-positive breast cancer therapies. Human epidermal growth factor receptor 2 (HER-2) protein, which results from genetic mutation and factors in about 1 in 5 breast cancers, can be extremely resistant to hormone therapies. Findings have led to ways to target the protein and decrease the promotion of new cancer cells.
One of her special areas of interest is postmenopausal women with breast cancer. Her focus is first on treating the cancer, but also on managing other issues such as bone density loss, gynecologic problems, cardiac disease, and weight management.
For patients, she says her work is even more powerful when combined with the team approach to care at UT Southwestern. Planning is truly integrated to benefit each patient. As part of a team, Dr. Haley combines her experience and knowledge with other breast cancer experts dedicated to providing a highly individualized, comprehensive approach to the patient.
Dr. Haley has been named to the Best Doctors in America list by U.S. News & World Report and Best Doctors in Dallas by D Magazine.
- Texas Medical Association & Dallas County Medical Society
- American Society of Hematology
- American Society of Clinical Oncology
- American College of Physicians Fellow
- ADA Honor Medical Association
- AOA Honor Society 1976, Distinguished Medical Student Award
- Best Doctors in Dallas 2001, Listed from 2001 to 2009
- Dorothy Faye Holt Kimsey 2006, Fund in Oncology
- Charles Cameron Sprague, M.D. 2006, Chair in Clinical Oncology
- Best Doctors in America 2009, Listed from 2005 - 2009
Zolendronic Acid Effectively Prevents Aromatase Inhibitor Associated Bone Loss in Pastmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36 month Follow-up Results
B Haley Clin Breast Cancer 9(2) 77-85
Assessment of HER-2/New Status in Breast Cancer
Wang S, Saboorian MH, Frenkel EP, Haley BB American Society of Clinical Pathology 2001 116 495-503
Custodianship of Genetic Information ClinicalChallenges and Professional Responsibility
Haley Journal of ClinicalOncology 2005 23
Nanoparticles for Drug Delivery in Cancer Treatment
Haley Urologic Oncology Seminars & Original Investigations 2008 26 57-64
- Zolendronic Acid Effectively Prevents Aromatase Inhibitor Associated Bone Loss in Pastmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36 month Follow-up Results
- Targeted Translational Research
- Breast Cancer
- Breast Cancers
- Medical Treatment of Breast Cancer
Q&A by Dr. Haley
Articles by Dr. Haley
Showing 1 locations